Fate Therapeutics Company

Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics.
The backstory is that while others were working towards therapies based on transplanting stem cell-derived cells into patients, Randall Moon (HHMI and University of Washington) and Alex Rives (Arch Venture Capitol) envisioned a different approach to develop regenerative therapies. The concept, based on data from hematopoietic progenitor cells, was that one could modulate the properties of stem cells in vivo using small molecules or biologics. They presented this idea to Arch Venture Capitol in Seattle, which launched the company, soon to be joined by other investors.
Technology: mHealth
Industry: P4 Medicine
Headquarters: United States
Founded Date: 2007
Employees Number: 11-50
Funding Status: IPO
Investors Number: 7
Total Funding: $360.2M
Estimated Revenue: $1M to $10M
Last Funding Type: Post-IPO Equity

Visit Website
info@fatetherapeutics.com
https://twitter.com/fatetherapeutic
Register and Claim Ownership